Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

I am searching for a
Reset Form
Gerald P. Linette, MD, PHD

Gerald P. Linette, MD, PHD Physician

Chief Medical Officer for Cancer Immunotherapy Clinical Director of the Parker Institute for Cancer Immunotherapy Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Linette is employed by Penn Medicine.

Call 800-789-7366 Request a Callback
No Patient Satisfaction Reviews
Why not?

There is no publicly available rating for this medical professional for one of the following reasons:

  1. He or she is not employed by Penn Medicine.
  2. He or she does not see patients in a medical practice setting.
  3. He or she sees patients but has not yet received the minimum 30 patient satisfaction reviews in the past 12 months, ensuring that the rating is statistically reliable and a true reflection of patient satisfaction.

About Dr. Gerald P. Linette

Recognized by America's Top Doctors for 2017

Recognized by Best in Doctors America 2015 - 2018

Recognized in Philadelphia magazine's annual Top Docs issues for 2018 and 2019

Clinical Specialties


  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 1999

Clinical Expertise:

  • Astrocytoma Tumors
  • Biological Targeted Therapy
  • Brain Metastasis
  • Brain Tumors
  • Cancer Chemotherapy
  • Central Nervous System Tumors
  • Immunotherapy
  • Metastatic Melanoma
  • Skin Cancer
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oscar Health Plan of PA
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Georgetown University School of Medicine
Residency: Barnes-Jewish Hospital - Washington University, St. Louis
Fellowship: Massachusetts General Hospital


American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National American Society of Immunologists, National Marsden Fund, The Royal Society of New Zealand Review Panel, International NCI, Cancer Immunopthology and Immunotherapy (CII) study section, National NCI, SPORE (P50) panel, National Oncopole EMC2 panel, International Rosetrees Trust, London Review Panel, International Swiss Cancer League, International

Hospital Affiliation

Dr. Linette is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Human Cancer Immunology is the focus of our laboratory and clinical efforts.

The development of a systematic approach to identify and validate cancer neoantigens is a primary interest of our research laboratory. In collaboration with experts in cancer genomics, we have created a bioinformatics pipeline to identify tumor-specific missense mutations which encode neoantigenic peptides. Our team has successfully applied this strategy to develop the first test of personalized cancer vaccination in humans with melanoma. Ongoing proof-of-concept trials aim to test neoantigens as targets for various immunotherapy strategies in melanoma and other solid tumors. In particular, our work aims to characterize the functional and phenotypic landscape of vaccine-elicited T cells using molecular technologies.

A related interest is the development of cellular therapies for cancer. We are currently exploring the development of neoantigen-specific T cell therapy for use in patients. We work collaboratively with research groups in order to find novel solutions to overcome the inherent obstacles created by the tumor microenvironment. The long term goal is to advance and test personalized medicine based approaches in cancer patients. For more information, please see the Center for Cellular Immunotherapies home page.

Selected Publications:

Linette GP, Carreno BM.: Neoantigen Vaccines Pass the Immunogenicity Test Trends Mol Med. : 2017.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.: Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. : 2017.

Zenga J, Nussenbaum B, Cornelius LA, Linette GP, Desai SC.: Management Controversies in Head and Neck Melanoma: A Systematic Review. JAMA Facial Plast Surg 19 (1): 53-62,2017.

Hodi FS1, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.: Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17 (11): 1558-1568,2016.

Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P.: Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17 (10): 1374-1385,2016.

Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, Griffith M: pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens Genome Med 8 (1): 11-19,2016.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372 (21): 2006-17,2015.

Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie WR, Hildebrand WH, Mardis ER, Linette GP.: A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (6236): 803-8,2015.

Ding L, Kim M, Dees ND, Kanchi KL, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, Weber JS.: Clonal Architecture and Driver Mutations in Metastatic Melanoma. PLOS One. 9 (11): 9e111153,2014.

Carreno BM, Becker-Hapak M, Huang A, Chan M, Alyasiry A, Lie WR, Aft RL, Cornelius LA, Trinkaus KM, Linette GP.: IL-12p70 producing patient DC vaccine elicits Tc1-polarized immunity. Journal of Clinical Investigation 123 (8): 3383-94,2013.

Academic Contact Info

University of Pennsylvania
Center for Cellular Immunotherapies
3400 Civic Center Blvd
SPE 8-102

Philadelphia, PA 19104
Phone: (215) 573-7032
Patient appointments: 800-789-7366 (PENN)